Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

Authors:

Abstract
No abstract available
Funding Information
  • National Cancer Institute of the National Institutes of Health (award numbers U10CA180821 and U10CA180882)

This publication has 24 references indexed in Scilit: